Producers jump amid speculation alcohol companies will make further inroads into sector
Producers jump amid speculation alcohol companies will make further inroads into sector
Canopy Growth Corporation (TSX: WEED) is proud to announce that it has agreed to enter into a strategic relationship with the leading total beverage alcohol supplier in the United States, Constellation Brands (NYSE: STZ and STZ.B).
New cannabinoid medicine can be successfully administered via a topical gel lens into the eye, a new InMed-University of British Columbia study reports.
Passage of a new law in Oregon that requires industrial hemp growers to register with the state is seen as a positive move for the industry, advocates of the program are saying.
Marijuana Company of America (OTC: MCOA) is a distinctive corporation utilizing a strategic business structure within this burgeoning industry.
InMed Pharmaceuticals develops technology to bridge the gap between synthetic and natural cannabinoids.
InMed Pharmaceuticals is a turnaround stock, with recent news updates showing promise for future gains
As it gets set to become the world's first legal recreational marijuana market, Canada is gearing up to be the main exporter for pot worldwide.
7,700 kg per annum facility to focus on high-margin concentrates, leveraging award-winning MPX brand.
Looking at how the expertise of InMed's management, consulting and advisory team combines to drive value for shareholders.
Payment solutions company Global Payout, Inc. (OTC: GOHE) this morning announced that its majority owned subsidiary, MoneyTrac Technology, Inc., is currently in the process of ramping-up its sales and marketing efforts within Los Angeles County for its newly-acquired PotSaver brand.
Specialized holding company SinglePoint, Inc. (OTC: SING) is the focus of a newly-released podcast interview announced this morning by Investorideas.com.
Grey Cloak Tech, Inc. (OTCQB: GRCK) today announced that its board of directors has decided to abandon and cancel the reverse stock split that was previously approved by both the board and the company’s shareholders in February 2017.
We think that InMed’s proprietary technology could put $6.6 Billion in play and make it one of the strongest biotech stocks in the market. We also think InMed is in the right place at the right time to create real value for investors in the Industry. Here's a few reasons why.
ChineseInvestors.com continues to rapidly grow in 2017, which is primarily attributed to the company’s focus on the CBD health products market.